Back

Pharma

6th Annual Highly Potent Active Pharmaceutical Ingredients Summit

  • 10th – 12th February 2021
  • Italy flag Italy Milan

The Highly Potent Active Pharmaceutical Ingredients Summit offers only the highest-profile of industry speakers presenting keynote topics, taking the experience to an all-new level.  

This event will provide you with access to other industry leaders and an environment to discuss process innovation, technology, and safety perspectives for both highly potent active pharmaceutical ingredient (HPAPI) manufacturers and outsourcers. We look forward to inspiring you in Italy! 

Read more

About

This event provides its participants access to other industry leaders and an environment to discuss process innovation and technology and safety perspectives for both highly potent active pharmaceutical ingredient (HPAPI) manufacturers and outsourcers.

This Summit will focus on current market trends for HPAPI, including process development and scale-up, cost-effective production, containment innovations and best manufacturing practices as well as regulatory updates.

We are delighted to give you this opportunity to participate at this Summit. We look forward to welcoming you in Milan in February!

Who Should Attend:

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Senior Managers, Principal Scientists, Prin­cipal Toxicologists, Fellows and Investigators spe­cialising in:

  • Business Development
  • Engineering
  • External Supply
  • Formulation Development
  • Health, Safety & Environment (HSE)
  • Industrial Hygiene
  • Laboratory Services
  • Manufacturing
  • New Products
  • New Technologies
  • Occupational Toxicology
  • Outsourcing
  • Process Development
  • Product Quality
  • Regulatory
  • Research & Development
  • Risk Assessments
  • Sales Development
  • Strategic Development
  • Validation

BOOK YOUR SEAT NOW

The Early Bird Offer expires in 25 days!

REQUEST A BROCHURE

To request an agenda for this Summit, please complete the details below. We will send you the agenda via email.

Key Practical Learning Points

  • EMA requirements and considerations
  • Assuring regulatory compliance with the permitted daily exposure
  • Avoiding major HPAPI project issues
  • Dealing with containment challenges
  • HPAPI facilities and process equipment design
  • Cleaning validation as one driver to prevent cross-contamination
  • How to ensure safe HPAPI Handling?
  • Enhance every stage of potent compound development strategy
  • How to improve safety and maximise manufacturing efficiencies for highly potent medicines
  • Advanced therapies: are they HPAPI?

BOOK YOUR SEAT NOW

The Early Bird Offer expires in 25 days!

Justin Mason-Home, UK

Director

HPAPI Project Services Limited

Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has worked glob­ally and held senior positions in potent biopharmaceutical occupational health and safety global environmental consulting, board level positions in a biotechnology company and also been involved in corporate environmental management. Justin has worked on mul­tiple ADC projects and specialises in technically complex and strategic projects, including unique experiences in managing sensitive highly potent and toxic biopharmaceutical compound matters.

Richard Denk, CH

Head of Containment Group

Skan AG, Switzerland

Richard Denk has studied mechanical engineering and did an examination on experts of GMP, qualification and validation, pharmaceutical auditing, pharmaceutical engineering and quality control at the Albstadt-Sigmaringen University of Applied Sciences in Germany. Richard works at SKAN AG, headquartered in Allschwil, as the head of sales containment. Eight years ago he founded the expert containment group of the ISPE D/A/CH, and in 2015 they published the Containment Manual. Richard has spent nearly 20 years with the production of highly active and highly hazardous substances and has developed the containment pyramid.

Martin Axon, UK

Principal Occupational Hygienist

SafeBridge Europe

Martin Axon is principal occupational hygienist for SafeBridge Europe and is a chartered fellow of the faculty of occupational hygiene. He has degrees in in­dustrial chemistry and environmental pollution science. He has over 25 years of experience working in the pharmaceutical industry in the UK and internationally, where, as an occupational hygienist for primary and secondary sites, he provid­ed support for potent pharmaceutical product manufacture. During mid-career, he was course director for a postgraduate programme in occupational hygiene, health and safety, at London South Bank University. Martin joined SafeBridge in 2005. His current role includes managing SafeBridge’s services in Europe and advising clients on the safe handling of potent pharmaceutical compounds in a range of environments, from laboratory scale through to secondary manufacture.

Justin Mason-Home, UK

Director

HPAPI Project Services Limited

Richard Denk, CH

Head of Containment Group

Skan AG, Switzerland

Martin Axon, UK

Principal Occupational Hygienist

SafeBridge Europe